Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BNM001
MIFTS: 43

Bone Marrow Cancer

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bone Marrow Cancer

About this section

MalaCards integrated aliases for Bone Marrow Cancer:

Name: Bone Marrow Cancer 12 15
Malignant Neoplasm of Bone Marrow 12 71
Chronic Myeloproliferative Disorder 71
Myeloproliferative Disorders 43
Malignant Bone Marrow Tumor 12
Myeloproliferative Disease 71
Bone Marrow Neoplasms 71
Bone Marrow Neoplasm 12
Bone Marrow Tumor 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Blood diseases Bone diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:4960
MeSH 43 D009196
SNOMED-CT 67 20921005
ICD10 32 D47.1
UMLS 71 C0027022 C0282609 C1292778 more
Sources

Summaries for Bone Marrow Cancer

About this section
Disease Ontology : 12 A hematopoietic cancer that derives from the blood-forming stem cells of the bone marrow.

MalaCards based summary : Bone Marrow Cancer, also known as malignant neoplasm of bone marrow, is related to myeloproliferative neoplasm and leukemia, chronic myeloid. An important gene associated with Bone Marrow Cancer is U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1), and among its related pathways/superpathways are MicroRNAs in cancer and Innate Lymphoid Cell Differentiation Pathways. The drugs Hydroxyurea and Nystatin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid.

Wikipedia : 74 Multiple myeloma (MM), also known as plasma cell myeloma, is a cancer of plasma cells, a type of white... more...

Sources

Related Diseases for Bone Marrow Cancer

About this section

Diseases related to Bone Marrow Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 530)
# Related Disease Score Top Affiliating Genes
1 myeloproliferative neoplasm 34.8 U2AF1 MIR17 MIR155 MIR126 LUC7L2 JAK2
2 leukemia, chronic myeloid 33.5 U2AF1 MIR9-1 MIR17 MIR155 MIR142 MIR126
3 myelodysplastic/myeloproliferative neoplasm 33.3 U2AF1 LUC7L2 JAK2
4 ocular cancer 32.8 U2AF1 MIR9-1 MIR199A1 MIR17 MIR142 MIR125A
5 diamond-blackfan anemia 32.4 U2AF1 LUC7L2 JAK2 CD34
6 pancytopenia 31.7 U2AF1 LUC7L2 IRF4 CD34
7 chronic neutrophilic leukemia 31.6 U2AF1 LUC7L2 JAK2 CD34
8 leukemia, acute myeloid 31.6 U2AF1 MIR9-1 MIR34A MIR21 MIR199A1 MIR181A1
9 megakaryocytic leukemia 31.5 U2AF1 KDM4C JAK2
10 atypical chronic myeloid leukemia 31.4 U2AF1 LUC7L2 JAK2
11 leukemia, acute lymphoblastic 31.4 U2AF1 MIR9-1 MIR21 MIR17 MIR155 MIR126
12 idiopathic interstitial pneumonia 31.2 MIR21 MIR199A1 MIR142 CD34 CCR6
13 chronic leukemia 31.2 U2AF1 LUC7L2 KDM4C JAK2 H2AC18
14 vascular disease 31.1 MIR21 MIR199A1 MIR126 MIR125A CD34
15 severe combined immunodeficiency 31.1 IRF4 ICOSLG H2AC18 CD34 CCR6
16 b-cell lymphoma 31.1 MIR21 MIR181A1 MIR17 MIR155 MIR142 JAK2
17 lymphoma, hodgkin, classic 31.0 MIR21 MIR155 KDM4C JAK2 IRF4 ICOSLG
18 leukemia, chronic lymphocytic 30.9 U2AF1 SDC1 MIR9-1 MIR34A MIR21 MIR199A1
19 neutrophilia, hereditary 30.9 U2AF1 LUC7L2 JAK2
20 monoclonal gammopathy of uncertain significance 30.8 U2AF1 SDC1 MIR126 ICOSLG CCR6
21 autosomal recessive disease 30.8 U2AF1 MIR9-1 MIR17 IRF4 H2AC18 CCR6
22 aortic valve disease 2 30.8 MIR34A MIR21 MIR199A1 MIR17 MIR126
23 mycobacterium tuberculosis 1 30.8 MIR21 MIR155 ICOSLG H2AC18 CCR6
24 exanthem 30.8 ICOSLG H2AC18 CCR6
25 thyroid gland papillary carcinoma 30.8 MIR9-1 MIR199A1 MIR181A1 MIR17 MIR125A
26 follicular lymphoma 30.8 MIR181A1 MIR17 MIR155 IRF4
27 blood platelet disease 30.8 U2AF1 LUC7L2 JAK2 ICOSLG H2AC18 CD34
28 heart septal defect 30.7 U2AF1 MIR199A1 H2AC18
29 dermatitis, atopic 30.7 MIR21 MIR155 MIR142 ICOSLG H2AC18 CCR6
30 sm-ahnmd 30.7 U2AF1 JAK2
31 diffuse large b-cell lymphoma 30.6 SDC1 MIR21 MIR199A1 MIR181A1 MIR17 MIR155
32 skin disease 30.6 MIR21 MIR199A1 MIR17 MIR155 MIR142 MIR126
33 polymyositis 30.6 MIR21 MIR155
34 diabetes mellitus, noninsulin-dependent 30.6 MIR21 MIR199A1 MIR17 MIR142 MIR126 MIR125A
35 systemic lupus erythematosus 30.6 SDC1 MIR21 MIR155 MIR142 MIR125A JAK2
36 lymphoma, non-hodgkin, familial 30.5 U2AF1 SDC1 MIR9-1 MIR34A MIR21 MIR199A1
37 arteries, anomalies of 30.5 MIR9-1 MIR34A MIR21 MIR199A1 MIR181A1 MIR17
38 ovarian cancer 30.4 MIR9-1 MIR34A MIR21 MIR199A1 MIR17 MIR155
39 myeloma, multiple 30.3 U2AF1 SDC1 MIR21 MIR199A1 MIR181A1 MIR17
40 hematologic cancer 30.2 U2AF1 SDC1 MIR9-1 MIR34A MIR21 MIR199A1
41 myeloproliferative disorder, chronic, with eosinophilia 12.7
42 pdgfrb-associated chronic eosinophilic leukemia 11.8
43 polycythemia vera 11.8
44 myelofibrosis 11.7
45 8p11 myeloproliferative syndrome 11.7
46 juvenile myelomonocytic leukemia 11.6
47 thrombocythemia 1 11.5
48 mastocytosis, cutaneous 11.5
49 budd-chiari syndrome 11.5
50 erythromelalgia 11.4

Graphical network of the top 20 diseases related to Bone Marrow Cancer:



Diseases related to Bone Marrow Cancer
Sources

Symptoms & Phenotypes for Bone Marrow Cancer

About this section
Sources

Drugs & Therapeutics for Bone Marrow Cancer

About this section

Drugs for Bone Marrow Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 401)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxyurea Approved Phase 3 127-07-1 3657
2
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
3
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
4
deoxycholic acid Approved Phase 3 83-44-3 222528
5
Perphenazine Approved Phase 3 58-39-9 4748
6
Baclofen Approved Phase 3 1134-47-0 2284
7
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
8
Amitriptyline Approved Phase 3 50-48-6 2160
9
Dalteparin Approved Phase 3 9005-49-6
10
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
11
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
12
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
13
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
14
Acyclovir Approved Phase 3 59277-89-3 2022
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
16
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
17
Fosaprepitant Approved Phase 3 172673-20-0 219090
18
Histamine Approved, Investigational Phase 3 51-45-6 774
19
Lenalidomide Approved Phase 3 191732-72-6 216326
20
Hydroxyzine Approved Phase 3 68-88-2 3658
21
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
22
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
23
Thioguanine Approved Phase 3 154-42-7 2723601
24
Sodium citrate Approved, Investigational Phase 3 68-04-2
25
Peginterferon alfa-2b Approved Phase 3 215647-85-1, 99210-65-8
26
Mycophenolic acid Approved Phase 3 24280-93-1 446541
27
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
28
Mercaptopurine Approved Phase 3 50-44-2 667490
29
Danazol Approved Phase 3 17230-88-5 28417
30
Ponatinib Approved, Investigational Phase 3 943319-70-8 24826799
31
tannic acid Approved Phase 3 1401-55-4
32
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
33
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
34
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
35
Polyestradiol phosphate Approved Phase 3 28014-46-2
36
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
37
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
38
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
39
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
40
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
41
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
42
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
43 Analgesics Phase 3
44 Antipsychotic Agents Phase 3
45 Central Nervous System Depressants Phase 3
46 Tranquilizing Agents Phase 3
47 Analgesics, Opioid Phase 3
48 Psychotropic Drugs Phase 3
49 Anti-Anxiety Agents Phase 3
50 Serotonin Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 558)
# Name Status NCT ID Phase Drugs
1 A UK Open-label, Multicentre, Exploratory Phase II Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
2 Busulfan Dose Escalation Study Based on AUC in the Setting of Busulfan/Fludarabine Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
3 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3
4 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
5 Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
6 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
7 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
8 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
9 A PROSPECTIVE RANDOMIZED, DOUBLE-BLIND, COMPARATIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF NYSTATIN AND AMPHOTERICIN B FOR EMPIRIC ANTIFUNGAL TREATMENT IN NEUTROPENIC PATIENTS Completed NCT00002742 Phase 3 amphotericin B deoxycholate;nystatin
10 An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available. Completed NCT02292446 Phase 3 Ruxolitinib
11 The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
12 A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy Completed NCT00003600 Phase 3
13 A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
14 An Open-label, Single Arm, Phase III Study to Assess the Self-administration of AOP2014 Using a Pre-filled Pen, Developed for the Treatment of Polycythemia Vera Patients Completed NCT02523638 Phase 3 Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
15 A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell-Transfusion-Dependence Completed NCT01178281 Phase 3 Pomalidomide 0.5 mg;Placebo;Pomalidomide
16 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
17 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
18 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
19 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
20 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
21 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
22 A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201) Completed NCT00075816 Phase 3
23 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
24 A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed NCT00322101 Phase 3 cyclophosphamide;mycophenolate mofetil;busulfan;cyclosporine;fludarabine phosphate;tacrolimus;methotrexate
25 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
26 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
27 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
28 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
29 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
30 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
31 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
32 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
33 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Versus Placebo in Anemic Patients With IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes Completed NCT01381809 Phase 3 Group 2: Placebo;Group 1: Epoetin alfa
34 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
35 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
36 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
37 A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2) Recruiting NCT03859427 Phase 3 Carfilzomib;Carfilzomib;Lenalidomide;Dexamethasone
38 Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates Examining Checkpoint Immune Regulators' Expression Recruiting NCT03480360 Phase 3 Cyclophosphamide;Fludarabine;Tacrolimus;cellcept;g-csf
39 Aprepitant Versus Hydroxyzine in Association With Cytoreductive Treatments for Patients With Myeloproliferative Neoplasia Suffering From Persistent Aquagenic Pruritus. Recruiting NCT03808805 Phase 3 Aprepitant 80 mg;Hydroxyzine 25mg;Placebo of Hydroxyzine;Placebo of Aprepitant
40 PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant Recruiting NCT01366612 Phase 3 Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose);Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
41 The Promoting Resilience in Stress Management (PRISM) Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation Recruiting NCT03640325 Phase 3
42 Tacrolimus, Mini-dose Methotrexate and Mycophenolate Mofetil Versus Tacrolimus and Methotrexate for the Prevention of Acute Graft-versus-Host-Disease Recruiting NCT01951885 Phase 3 tacrolimus;methotrexate;Mycophenolate mofetil;Methotrexate (low dose)
43 Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome Recruiting NCT02521493 Phase 3 Asparaginase;Asparaginase Erwinia chrysanthemi;Cytarabine;Daunorubicin;Daunorubicin Hydrochloride;Etoposide;Mitoxantrone;Mitoxantrone Hydrochloride;Thioguanine
44 A Phase 3b, Open Label, Single-arm Rollover Study to Evaluate Long Term Safety in Subjects Who Have Participated in Other Luspatercept (Ace-536) Clinical Trials. Recruiting NCT04064060 Phase 3 Luspatercept
45 Randomized, Open Label, Multicenter Phase IIIb Study Evaluating the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant (Response 2) Active, not recruiting NCT02038036 Phase 3 Best Available Therapy;ruxolitinib
46 A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib Active, not recruiting NCT02627677 Phase 3 ponatinib 30 mg QD;ponatinib 15 mg QD;nilotinib 400 mg BID
47 A Randomized, Double-Blind, Phase 3 Study of Momelotinib vs Danazol in Symptomatic, Anemic Subjects With Previously JAKi Treated Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis Active, not recruiting NCT04173494 Phase 3 Momelotinib;Danazol;Placebo to match momelotinib;Placebo to match danazol
48 An Open-label, Multicenter, Phase IIIb Study Assessing the Long-term Efficacy and Safety of AOP2014 and Standard First Line Treatment (BAT) in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study Active, not recruiting NCT02218047 Phase 3 Pegylated-Proline-interferon alpha-2b;Best available therapy (BAT)
49 Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Fludarabine-Melphalan Versus Fludarabine-Melphalan-ATG Reduced-intensity Conditioning: a Phase III Randomized Study From the Belgian Hematology Society (BHS) Suspended NCT03852407 Phase 3 Thymoglobulin;Melphalan;Fludarabine
50 Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis Terminated NCT01749111 Phase 3 ARM A Cyclophosphamide;ARM B Calcineurin inhibitor and methotrexate

Search NIH Clinical Center for Bone Marrow Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Sodium phenylbutyrate

Cochrane evidence based reviews: myeloproliferative disorders

Sources

Genetic Tests for Bone Marrow Cancer

About this section
Sources

Anatomical Context for Bone Marrow Cancer

About this section

MalaCards organs/tissues related to Bone Marrow Cancer:

40
Bone, Bone Marrow, Myeloid, T Cells, B Cells, Breast, Heart
Sources

Publications for Bone Marrow Cancer

About this section

Articles related to Bone Marrow Cancer:

(show all 36)
# Title Authors PMID Year
1
Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis. 61
31256359 2020
2
Proteasome inhibition in multiple myeloma - lessons for other cancers. 61
31875696 2019
3
Exploration of quinolone and quinoline derivatives as potential anticancer agents. 61
31410781 2019
4
Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics. 61
31217335 2019
5
Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review. 61
30679915 2019
6
Persistent Exposure to Fusobacterium nucleatum Triggers Chemokine/Cytokine Release and Inhibits the Proliferation and Osteogenic Differentiation Capabilities of Human Gingiva-Derived Mesenchymal Stem Cells. 61
31921705 2019
7
Biochemical mechanisms implemented by human acute myeloid leukemia cells to suppress host immune surveillance. 61
29872115 2018
8
Distinctive inhibition of alkaline phosphatase isozymes by thiazol-2-ylidene-benzamide derivatives: Functional insights into their anticancer role. 61
29363794 2018
9
Detailed investigation of anticancer activity of sulfamoyl benz(sulfon)amides and 1H-pyrazol-4-yl benzamides: An experimental and computational study. 61
29763580 2018
10
Prolonged intracellular accumulation of light-inducible nanoparticles in leukemia cells allows their remote activation. 61
28492285 2017
11
Readmissions After Surgical Resection of Metastatic Tumors of the Spine at a Single Institution. 61
28254537 2017
12
Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line. 61
28122281 2017
13
Distinct oncogenic Ras signals characterized by profound differences in flux through the RasGDP/RasGTP cycle. 61
27159504 2017
14
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. 61
27809856 2016
15
A Personalized Framework for Dynamic Modeling of Disease Trajectories in Chronic Lymphocytic Leukemia. 61
26929022 2016
16
Mesenchymal Stem Cell-Derived Exosomes Stimulate Cycling Quiescence and Early Breast Cancer Dormancy in Bone Marrow. 61
27569215 2016
17
Inhibitory effect of epirubicin-loaded lipid microbubbles with conjugated anti-ABCG2 antibody combined with therapeutic ultrasound on multiple myeloma cancer stem cells. 61
26204324 2016
18
Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia. 61
25218571 2014
19
Mayo breakthrough: virus may destroy bone marrow cancer. 61
25233543 2014
20
A case of multiple myeloma presenting as scalp swelling with intracranial extension. 61
24347954 2013
21
Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. 61
22879387 2012
22
Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. 61
22696376 2012
23
Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. 61
22395247 2012
24
The proto-oncoprotein KR-POK represses transcriptional activation of CDKN1A by MIZ-1 through competitive binding. 61
21804610 2012
25
Detection of PIK3CA Mutations in Breast Cancer Bone Metastases. 61
22970388 2012
26
Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. 61
21901718 2011
27
Hematological and toxicological evaluation of formaldehyde as a potential cause of human leukemia. 61
20729258 2011
28
Future novel single agent and combination therapies. 61
20010171 2009
29
The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells. 61
19342998 2009
30
Seleno-L-Methionine Modulation of Nucleotide Excision DNA Repair Relevant to Cancer Prevention and Chemotherapy. 61
20336178 2009
31
Thalidomide in multiple myeloma. 61
16433584 2006
32
Gene therapy in pediatric surgery. 61
8858767 1996
33
Bone marrow chromosome abnormalities in breast cancer in patients following adjuvant chemotherapy. 61
7471052 1980
34
Erythrokinetics and androgens in bone marrow cancer. 61
975001 1976
35
[Heterogeneity of immunoreactive calcitonin in the plasma of patients with bone marrow cancer]. 61
772524 1975
36
[Relation between multiple myeloma (Rusticki-Kaller disease) & metastatic bone marrow cancer based on 2 personal case reports]. 61
13587007 1957
Sources

Variations for Bone Marrow Cancer

About this section
Sources

Expression for Bone Marrow Cancer

About this section
Search GEO for disease gene expression data for Bone Marrow Cancer.
Sources

Pathways for Bone Marrow Cancer

About this section

Pathways related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MicroRNAs in cancer 36
11.77 MIR9-1 MIR34A MIR21 MIR199A1 MIR181A1 MIR17
2
Innate Lymphoid Cell Differentiation Pathways 64
11.23 IRF4 CD34 CCR6
3
Cell Differentiation - Index 1
10.71 MIR9-1 MIR199A1 MIR181A1
Sources

GO Terms for Bone Marrow Cancer

About this section

Cellular components related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 MIR21 MIR199A1 MIR181A1 MIR17 MIR155 MIR142

Biological processes related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.91 MIR34A MIR21 MIR155 MIR125A KDM4C CD34
2 positive regulation of angiogenesis GO:0045766 9.84 MIR21 MIR199A1 MIR126 CD34
3 cellular response to hypoxia GO:0071456 9.81 MIR34A MIR17 MIR155 MIR126
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.77 MIR21 MIR126 JAK2
5 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.72 MIR21 MIR17 JAK2
6 positive regulation of inflammatory response GO:0050729 9.71 MIR21 MIR155 MIR126 JAK2
7 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.7 MIR21 MIR199A1 JAK2
8 positive regulation of sprouting angiogenesis GO:1903672 9.65 MIR155 MIR126 MIR125A
9 positive regulation of activated T cell proliferation GO:0042104 9.63 MIR21 MIR155 ICOSLG
10 negative regulation of gene expression GO:0010629 9.63 MIR21 MIR181A1 MIR17 MIR155 MIR125A CD34
11 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.61 MIR21 MIR181A1
12 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.6 MIR17 MIR155
13 positive regulation of microglial cell activation GO:1903980 9.58 MIR155 MIR142
14 positive regulation of metalloendopeptidase activity GO:1904685 9.58 MIR21 MIR17
15 negative regulation of regulatory T cell differentiation GO:0045590 9.57 MIR21 MIR155
16 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.56 MIR21 MIR17
17 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.54 MIR199A1 MIR17 MIR155
18 positive regulation of connective tissue replacement GO:1905205 9.5 MIR34A MIR199A1 MIR155
19 negative regulation of vascular wound healing GO:0061044 9.49 MIR34A MIR155
20 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.43 MIR199A1 MIR17 MIR155
21 miRNA mediated inhibition of translation GO:0035278 9.35 MIR9-1 MIR21 MIR181A1 MIR17 MIR155
22 gene silencing by miRNA GO:0035195 9.28 MIR125A MIR126 MIR155 MIR17 MIR181A1 MIR199A1

Molecular functions related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR9-1 MIR34A MIR21 MIR199A1 MIR181A1 MIR17
Sources

Sources for Bone Marrow Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....